Drug giant Amgen (AMGN) rebounded after hours from a 1% drop, rising 5 cents to $55.76 following the company’s announcement of Q4 sales and profit shy of estimates. Q4 sales of $3.8 billion missed analysts’ estimates for $3.85 billion, while and profit per share of $1.05 was well short of the average $1.13 estimate.
For this year, the company forecast sales of $15.1 billion to $15.5 billion and profit per share of $5.05 to $5.25, which at the midpoint is consistent with analysts’ estimates.
Amgen shares closed down 89 cents, or 1.6%, at $55.71 during the regular session.
No comments:
Post a Comment